Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A111E5 | ISIN: SE0002591420 | Ticker-Symbol: 24T
Tradegate
11.02.26 | 17:48
0,144 Euro
-1,57 % -0,002
Branche
Hardware
Aktienmarkt
Sonstige
1-Jahres-Chart
TOBII AB Chart 1 Jahr
5-Tage-Chart
TOBII AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,1440,14811.02.
0,1440,14811.02.
GlobeNewswire (Europe)
973 Leser
Artikel bewerten:
(2)

TOBII AB: Tobii secures design win for Get Set Early - Provides eye tracking for early autism screening

The eye tracking-based autism spectrum disorder screening tool aims to enable earlier detection and treatment through scientifically designed eye tracking tests.

Tobii, the global leader in eye tracking and pioneer of attention computing has secured a design win for Get Set Early, an autism spectrum disorder (ASD) screening tool designed to uncover early signs of autism in children as young as 12 months. The screening tool, developed by Psychology professor Dr. Karen Pierce and her team at UC San Diego and expanded by Butterfly Learnings, is the first of its kind in India to receive a CDSO certification and be approved for clinical use.

Early detection critical for effective therapy

Research shows that children diagnosed with autism before age two experience better language, cognitive, and social development. The brain is most adaptable in the first few years of life, making early detection crucial for effective therapy. Get Set Early enables early detection through the non-invasive nature of the test, letting children watch a short video while the system tracks eye movements to measure how long they focus on different types of stimuli. From this test, objective biomarkers for autism spectrum disorder are provided, making the assessment reliable and unbiased. The test is based on a patented and scientifically validated method that uses eye movements to detect signs of autism in children, developed by Dr. Karen Pierce, co-Director of Autism Center of Excellence, University of California, San Diego.

"Partnering with Tobii allows us to deliver gold-standard eye-tracking diagnostics for early autism screening across India and global markets. This is a powerful step forward in our mission to make high-quality, technology-driven screening accessible to every child, everywhere. We look forward to scaling this partnership globally." said Abhishek Sen, Co-Founder & CEO, Butterfly Learnings.

Eye tracking enabled by the Tobii Eye Tracker 5L

Tobii will provide Butterfly Learnings with the Tobii Eye Tracker 5L for integration into the Get Set Early screening tool. The Tobii Eye Tracker 5L is a high-performance eye tracker designed for seamless integration into digital health platforms, diagnostic tools, and cognitive assessment products.

"It's an honor for Tobii to be part of a product that can really make a change in people's lives. We are truly impressed with what Butterfly Learnings have achieved with the Get Set Early tool, building on fundamental research insights and converting them into real world use that is clinically approved, accessible, and scalable." said Emma Bauer, senior vice president, Integrations, at Tobii.

The Get Set Early screening tool is currently being implemented out across clinics all over India. For the development and integration of Tobii's Eye tracking technology into the screening tool, Butterfly Learnings and Tobii worked together with Tiden Technologies, the Indian reseller of Tobii's products, specialized in research grade technologies for neuroscience.

You can learn more about Tobii Eye Tracker 5L here.

For more information, please contact:
Rasmus Löwenmo Buckhöj, Head of Communications, Tobii AB, phone: +46 (0)73 327 87 64, email: rasmus.lowenmobuckhoj@tobii.com

About Tobii
Tobii is the global leader in eye tracking and pioneer of attention computing. We are on a mission to improve the world with technology that understands human attention and intent. Creating tech for a better future, our technologies and solutions apply to areas such as behavioral studies and research, healthcare, education and training, gaming, extended reality, automotive, and many more. Tobii's eye tracking is used by thousands of enterprises, universities, and research institutes around the globe. Headquartered in Sweden, Tobii is listed on Nasdaq Stockholm (TOBII). For more information: www.tobii.com.

About Butterfly Learnings:
Butterfly Learnings is a healthcare-led neurodevelopmental platform focused on early identification, therapy, and inclusive education for children with developmental and learning differences. Built on evidence-based clinical practices, Butterfly integrates diagnostics, multidisciplinary therapy, and school readiness programs to deliver measurable outcomes for children and families. With a strong emphasis on early intervention, clinical rigor, and scalable delivery, Butterfly Learnings works closely with pediatricians, therapists, and educators to ensure timely support during the most critical years of brain development
www.butterflylearnings.com

About Tiden Technologies
Tiden Technologies specializes in advanced human behavioral and neuroscientific technologies, including eye tracking and neuro-sensing solutions. As Tobii AB's regional distribution partner, it has enabled widespread adoption of eye-tracking applications across academic research, healthcare, defense, UX, and automotive sectors. For further information visit: www.tidentech.com

© 2026 GlobeNewswire (Europe)
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.